Last reviewed · How we verify
NCT05943041
Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
Phase 1 trial testing GB104(Level 1) in Solid Tumor in 9 participants. Completed in 22 December 2023.
22 December 2023
Quick facts
| Lead sponsor | GILongevity |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 28 April 2023 |
| Primary completion | 22 December 2023 |
| Estimated completion | 22 December 2023 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- GB104(Level 1) — full drug profile →
- GB104(Level 2) — full drug profile →
- GB104(Level 3) — full drug profile →
Conditions studied
- Solid Tumor — all drugs for Solid Tumor →
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Sigmoid Colon Cancer — all drugs for Sigmoid Colon Cancer →
- Rectosigmoid Junction Cancer — all drugs for Rectosigmoid Junction Cancer →
Sponsor
GILongevity — full company profile →
Who can join
19 and older, any sex, with Solid Tumor or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective, open label, multi-dose, sequential dose escalation, single-center, Phase 1 trial
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Preoperative metronidazole treatment to evaluate its efficacy in reducing <i>Fusobacterium nucleatum</i> colonisation in colorectal cancer patients: a proof-of-concept trial.
De Dosso S, Christoforidis D, Merlo E, Vannelli A, et al · · 2025 · PMID 41646257 · DOI 10.1016/j.esmogo.2025.100169
Verify or expand the search:
- PubMed search for NCT05943041
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor
Currently open trials in the same condition.
- NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
- NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05943041 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GILongevity
- Last refreshed: 14 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05943041.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing